Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 5/20 | 0.69 |
| ▸ | GABRA5 | P31644 | 5/20 | 0.69 |
| ▸ | GABRA3 | P34903 | 5/20 | 0.69 |
| ▸ | GABRA2 | P47869 | 5/20 | 0.69 |
| ▸ | GABRB2 | P47870 | 4/20 | 0.69 |
| ▸ | GABRG2 | P18507 | 3/20 | 0.69 |
| ▸ | GABRB3 | P28472 | 3/20 | 0.69 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.66 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.60 |
| ▸ | CNR1 | P21554 | 1/20 | 0.60 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.60 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.60 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.56 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | HPGD | P15428 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.55 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5490974 | 0.92 | KMT2A (0.61) | GABRA1GABRA5GABRA3GABRA2GABRB2 | |
| SCHEMBL1421181 | 0.89 | KMT2A (0.82) | GABRA1GABRA5GABRA3GABRA2GABRB2 | |
| Ro-052921 SCHEMBL29979594 | 0.82 | GABRA1 (1.00) | GABRA1GABRA5GABRA3GABRA2GABRB2 | |
| Ro-052921 SCHEMBL1365706 | 0.82 | GABRA1 (1.00) | GABRA1GABRA5GABRA3GABRA2GABRB2 | |
| SCHEMBL5349682 | 0.80 | TUBB4A (0.72) | GABRA1GABRA5GABRA3GABRA2GABRB2 | |
| SCHEMBL5034663 | 0.79 | KMT2A (0.54) | GABRA1GABRA5GABRA3GABRA2GABRB2 | |
| SCHEMBL5037318 | 0.77 | GABRA1 (0.56) | GABRA1GABRA5GABRA3GABRA2GABRB2 | |
| SCHEMBL18166499 | 0.77 | GABRA1 (0.56) | GABRA1GABRA5GABRA3GABRA2GABRB2 | |
| SCHEMBL6627733 | 0.76 | TUBB4A (0.67) | GABRA1GABRA5GABRA3GABRA2GABRB2 | |
| SCHEMBL5497070 | 0.76 | GABRA1 (0.62) | GABRA1GABRA5GABRA3GABRA2GABRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170000749-A1 | Methods for Treating Cognitive Disorders Using Inhibitors of Histone Deacetylase | FMR LLC | 2017-01-05 | — | — | US | disclosed |
| US-20170000749-A1 | Methods for Treating Cognitive Disorders Using Inhibitors of Histone Deacetylase | FMR LLC | 2017-01-05 | — | — | US | disclosed |
| US-20160222026-A1 | Dibenzo[B,F][1,4]oxazepin-11-yl-N-Hydroxybenzamides as HDAC Inhibitors | FMR LLC | 2016-08-04 | — | — | US | disclosed |
| US-20160222026-A1 | Dibenzo[B,F][1,4]oxazepin-11-yl-N-Hydroxybenzamides as HDAC Inhibitors | FMR LLC | 2016-08-04 | — | — | US | disclosed |
| EP-2966078-A2 | Inhibitors of histone deacetylase | MethylGene Inc. (CA) | 2016-01-13 | — | — | EP | disclosed |
| EP-2966078-A2 | Inhibitors of histone deacetylase | MethylGene Inc. (CA) | 2016-01-13 | — | — | EP | disclosed |
| US-9193749-B2 | Dibenzo[b,f][1,4]oxazepin-11-yl-N-hydroxybenzamides as HDAC inhibitors | FORUM PHARMACEUTICALS, INC. (US) | 2015-11-24 | — | — | US | disclosed |
| US-9193749-B2 | Dibenzo[b,f][1,4]oxazepin-11-yl-N-hydroxybenzamides as HDAC inhibitors | FORUM PHARMACEUTICALS, INC. (US) | 2015-11-24 | — | — | US | disclosed |
| US-20150080325-A1 | METHODS FOR TREATING COGNITIVE DISORDERS USING INHIBITORS OF HISTONE DEACETYLASE | ENVIVO PHARMACEUTICALS, INC. (US) | 2015-03-19 | — | — | US | disclosed |
| US-20150080325-A1 | METHODS FOR TREATING COGNITIVE DISORDERS USING INHIBITORS OF HISTONE DEACETYLASE | ENVIVO PHARMACEUTICALS, INC. (US) | 2015-03-19 | — | — | US | disclosed |
| US-20110288070-A1 | METHODS FOR TREATING COGNITIVE DISORDERS USING INHIBITORS OF HISTONE DEACETYLASE | FMR LLC | 2011-11-24 | — | — | US | disclosed |
| US-20110288070-A1 | METHODS FOR TREATING COGNITIVE DISORDERS USING INHIBITORS OF HISTONE DEACETYLASE | FMR LLC | 2011-11-24 | — | — | US | disclosed |
| US-20110196147-A1 | INHIBITORS OF HISTONE DEACETYLASE | FMR LLC | 2011-08-11 | — | — | US | disclosed |
| US-20110196147-A1 | INHIBITORS OF HISTONE DEACETYLASE | FMR LLC | 2011-08-11 | — | — | US | disclosed |
| EP-2343286-A1 | Dibenzo[b,f][1,4]oxazepine derivatives as inhibitors of histone deacetylase | Methylgene, Inc. (CA) | 2011-07-13 | — | — | EP | disclosed |
| WO-2009137462-A2 | METHODS FOR TREATING COGNITIVE DISORDERS USING INHIBITORS OF HISTONE DEACETYLASE | ENVIVO PHARMACEUTICALS, INC. (US) | 2009-11-12 | — | — | WO | disclosed |
| US-20080207590-A1 | Inhibitors of Histone Deacetylase | METHYLGENE INC. (CA) | 2008-08-28 | — | — | US | disclosed |
| US-20080207590-A1 | Inhibitors of Histone Deacetylase | METHYLGENE INC. (CA) | 2008-08-28 | — | — | US | disclosed |
| US-20080207590-A1 | Inhibitors of Histone Deacetylase | METHYLGENE INC. (CA) | 2008-08-28 | — | — | US | disclosed |
| WO-2008055068-A2 | INHIBITORS OF HISTONE DEACETYLASE | METHYLGENE INC. (CA) | 2008-05-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110288070-A1 | METHODS FOR TREATING COGNITIVE DISORDERS USING INHIBITORS OF HISTONE DEACETYLASE | HDAC1, HDAC5, HDAC2 | GABRA1 1167/4885GABRA5 811/4885GABRA3 1004/4885 |
| US-20080207590-A1 | Inhibitors of Histone Deacetylase | HDAC1, HDAC5, HDAC11 | GABRA1 3480/4885GABRA5 3071/4885GABRA3 3389/4885 |
| US-20150080325-A1 | METHODS FOR TREATING COGNITIVE DISORDERS USING INHIBITORS OF HISTONE DEACETYLASE | HDAC1, HDAC5, HDAC2 | GABRA1 1167/4885GABRA5 811/4885GABRA3 1004/4885 |
| US-20170000749-A1 | Methods for Treating Cognitive Disorders Using Inhibitors of Histone Deacetylase | HDAC5, KAT2A, HDAC1 | GABRA1 1206/4885GABRA5 812/4885GABRA3 984/4885 |
| US-20160222026-A1 | Dibenzo[B,F][1,4]oxazepin-11-yl-N-Hydroxybenzamides as HDAC Inhibitors | HDAC1, HDAC2, HDAC4 | GABRA1 1228/4885GABRA5 1407/4885GABRA3 1380/4885 |
| US-20110196147-A1 | INHIBITORS OF HISTONE DEACETYLASE | HDAC1, HDAC5, HDAC11 | GABRA1 3480/4885GABRA5 3071/4885GABRA3 3389/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.